GSK today announced $139 million of new investment in its biopharmaceutical manufacturing site in Rockville, MD to support growing demand for BENLYSTA® (belimumab) for adult patients with active, autoantibody-positive, systemic lupus erythematosus (SLE) who are receiving standard therapy.
{iframe}https://finance.yahoo.com/news/gsk-invests-139-million-expand-140500970.html{/iframe}